• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

异常凝血酶原(PIVKA-II)水平对预测中国乙型肝炎病毒相关性肝细胞癌患者微血管侵犯及肿瘤细胞增殖的意义

Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma.

作者信息

Ma Xiao-Lu, Zhu Jing, Wu Jiong, Tian Lu, Gao Yao-Yi, Zhang Chun-Yan, Zhou Yan, Dai Qian, Wang Bei-Li, Pan Bai-Shen, Zhou Jian, Fan Jia, Yang Xin-Rong, Guo Wei

机构信息

Department of Laboratory Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China.

Department of Liver Surgery, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Shanghai 200032, P.R. China.

出版信息

Oncol Lett. 2018 Jun;15(6):8396-8404. doi: 10.3892/ol.2018.8375. Epub 2018 Mar 29.

DOI:10.3892/ol.2018.8375
PMID:29805574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5950517/
Abstract

The present study aimed to determine the levels of prothrombin induced by vitamin K absence-II (PIVKA-II) according to the Barcelona Clinic Liver Cancer (BCLC) staging system, to develop an appropriate strategy for managing hepatocellular carcinoma (HCC), particularly early HCC, and to investigate the value of PIVKA-II for predicting prognosis-associated pathological parameters. Clinical information of 117 patients with hepatitis B-associated HCC was retrospectively collected. Preoperative serum PIVKA-II and α-fetoprotein (AFP) levels were measured using a chemiluminescence method. The efficiency of PIVKA-II levels for predicting pathological parameters was evaluated using step-wise logistic regression. The receiver operator characteristic curve was used to evaluate the predictive performance of PIVKA-II levels. It was demonstrated that except for the difference between stages B and C HCC (P=0.923), serum PIVKA-II levels significantly increased according to BCLC stage (P<0.050), however AFP levels did not. In early HCC (stage 0+A), the correlation between PIVKA-II and AFP levels (dual-positive, 64.70% in stage 0; 46.97% in stage A) was relatively weak (r=0.410). PIVKA-II >40 mAU/ml was an independent predictor of microvascular invasion [hazard ratio (HR), 3.77; 95% confidence interval (CI), 1.31-10.88; P=0.014; and high Ki67 expression (HR, 2.99; 95% CI, 1.19-7.52; P=0.020). Combined analysis of PIVKA and AFP levels may contribute to an effective strategy for the management of patients with early HCC, as high PIVKA-II levels indicated a more aggressive tumor phenotype. Further investigation of PIVKA-II levels may provide novel insights into the mechanism underlying the metastasis of HCC cells and facilitate the development of novel therapeutic strategies for HCC.

摘要

本研究旨在根据巴塞罗那临床肝癌(BCLC)分期系统确定维生素K缺乏诱导蛋白-II(PIVKA-II)水平,制定管理肝细胞癌(HCC)尤其是早期HCC的合适策略,并研究PIVKA-II对预测预后相关病理参数的价值。回顾性收集了117例乙型肝炎相关HCC患者的临床信息。采用化学发光法检测术前血清PIVKA-II和甲胎蛋白(AFP)水平。使用逐步逻辑回归评估PIVKA-II水平预测病理参数的效能。采用受试者工作特征曲线评估PIVKA-II水平的预测性能。结果表明,除了B期和C期HCC之间的差异外(P=0.923),血清PIVKA-II水平根据BCLC分期显著升高(P<0.050),而AFP水平则不然。在早期HCC(0+A期)中,PIVKA-II与AFP水平之间的相关性(双阳性,0期为64.70%;A期为46.97%)相对较弱(r=0.410)。PIVKA-II>40 mAU/ml是微血管侵犯的独立预测因素[风险比(HR),3.77;95%置信区间(CI),1.31-10.88;P=0.014]以及高Ki67表达(HR,2.99;95%CI,1.19-7.52;P=0.020)。PIVKA和AFP水平的联合分析可能有助于制定早期HCC患者的有效管理策略,因为高PIVKA-II水平表明肿瘤表型更具侵袭性。对PIVKA-II水平的进一步研究可能为HCC细胞转移的潜在机制提供新见解,并促进HCC新治疗策略的开发。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e37/5950517/c3c9e6a3924c/ol-15-06-8396-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e37/5950517/998e5c9c7675/ol-15-06-8396-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e37/5950517/6ecb81ca8158/ol-15-06-8396-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e37/5950517/c3c9e6a3924c/ol-15-06-8396-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e37/5950517/998e5c9c7675/ol-15-06-8396-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e37/5950517/6ecb81ca8158/ol-15-06-8396-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6e37/5950517/c3c9e6a3924c/ol-15-06-8396-g02.jpg

相似文献

1
Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma.异常凝血酶原(PIVKA-II)水平对预测中国乙型肝炎病毒相关性肝细胞癌患者微血管侵犯及肿瘤细胞增殖的意义
Oncol Lett. 2018 Jun;15(6):8396-8404. doi: 10.3892/ol.2018.8375. Epub 2018 Mar 29.
2
Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.血清 PIVKA-II 水平对 BCLC 早期肝细胞癌的诊断价值及其与 HBV DNA 的相关性。
Cancer Biomark. 2018;23(2):235-242. doi: 10.3233/CBM-181402.
3
Diagnostic value of prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) for early stage HBV related hepatocellular carcinoma.维生素K缺乏或拮抗剂-II诱导的凝血酶原(PIVKA-II)对早期HBV相关肝细胞癌的诊断价值
Infect Agent Cancer. 2017 Aug 23;12:47. doi: 10.1186/s13027-017-0153-6. eCollection 2017.
4
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis.血清 PIVKA-II 和甲胎蛋白在病毒学缓解时可预测乙型肝炎相关肝硬化患者的肝细胞癌。
J Formos Med Assoc. 2022 Mar;121(3):703-711. doi: 10.1016/j.jfma.2021.08.003. Epub 2021 Aug 25.
5
PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.PIVKA-II 可作为 AFP 的补充生物标志物,用于肝癌的诊断。
BMC Cancer. 2021 Apr 13;21(1):401. doi: 10.1186/s12885-021-08138-3.
6
Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma.异常凝血酶原和甲胎蛋白在乙型肝炎病毒相关性肝细胞癌中的诊断价值
World J Gastroenterol. 2015 Apr 7;21(13):3928-35. doi: 10.3748/wjg.v21.i13.3928.
7
Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion.异常凝血酶原(PIVKA-II)在早期肝细胞癌诊断和微血管侵犯预测中的性能。
J Hepatol. 2015 Apr;62(4):848-54. doi: 10.1016/j.jhep.2014.11.005. Epub 2014 Nov 11.
8
Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.甲胎蛋白及维生素K缺乏或拮抗剂-II诱导蛋白在乙型肝炎病毒相关肝细胞癌中的预后价值:一项前瞻性研究
J Clin Gastroenterol. 2009 May-Jun;43(5):482-8. doi: 10.1097/MCG.0b013e318182015a.
9
Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.甲胎蛋白异质体 3 和异常凝血酶原在总甲胎蛋白指导下对肝细胞癌的诊断价值。
World J Gastroenterol. 2013 Jan 21;19(3):339-46. doi: 10.3748/wjg.v19.i3.339.
10
The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.单独或联合检测血清 PIVKA-II 和 AFP 对中国肝细胞癌患者的诊断价值。
Dis Markers. 2021 Feb 8;2021:8868370. doi: 10.1155/2021/8868370. eCollection 2021.

引用本文的文献

1
Current Advancements in Serum Protein Biomarkers for Hepatitis B Virus-Associated Hepatocyte Remodeling and Hepatocellular Carcinoma.用于乙肝病毒相关肝细胞重塑和肝细胞癌的血清蛋白生物标志物的当前进展
Immun Inflamm Dis. 2025 Apr;13(4):e70171. doi: 10.1002/iid3.70171.
2
Tumor burden score combined with AFP and PIVKA-II (TAP score) to predict the prognosis of hepatocellular carcinoma patients after radical liver resection.肿瘤负荷评分联合甲胎蛋白和异常凝血酶原(TAP评分)用于预测肝细胞癌患者根治性肝切除术后的预后。
Langenbecks Arch Surg. 2025 Mar 6;410(1):89. doi: 10.1007/s00423-025-03650-7.
3
Alpha-fetoprotein-to-PIVKA-II ratio as a potential biomarker for hepatocellular carcinoma differentiation, imaging characteristics, and patient survival.

本文引用的文献

1
Bi-directional roles of IRF-1 on autophagy diminish its prognostic value as compared with Ki67 in liver transplantation for hepatocellular carcinoma.与Ki67相比,IRF-1在自噬中的双向作用降低了其在肝细胞癌肝移植中的预后价值。
Oncotarget. 2016 Jun 21;7(25):37979-37992. doi: 10.18632/oncotarget.9365.
2
Mechanisms of HBV-induced hepatocellular carcinoma.HBV 诱导肝细胞癌的机制。
J Hepatol. 2016 Apr;64(1 Suppl):S84-S101. doi: 10.1016/j.jhep.2016.02.021.
3
Diagnostic Evaluation of Des-Gamma-Carboxy Prothrombin versus α-Fetoprotein for Hepatitis B Virus-Related Hepatocellular Carcinoma in China: A Large-Scale, Multicentre Study.
甲胎蛋白与异常凝血酶原-II比值作为肝细胞癌分化、影像学特征及患者生存的潜在生物标志物。
Transl Cancer Res. 2024 Nov 30;13(11):5929-5942. doi: 10.21037/tcr-24-958. Epub 2024 Nov 14.
4
Diagnostic and prognostic performances of GALAD score in staging and 1-year mortality of hepatocellular carcinoma: A prospective study.GALAD 评分在肝细胞癌分期和 1 年死亡率中的诊断和预后性能:一项前瞻性研究。
World J Gastroenterol. 2024 May 7;30(17):2343-2353. doi: 10.3748/wjg.v30.i17.2343.
5
Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region.联合检测 PIVKA-II 和 AFP 在亚太地区肝细胞癌监测和随访中的应用。
Clin Mol Hepatol. 2023 Apr;29(2):277-292. doi: 10.3350/cmh.2022.0212. Epub 2023 Jan 30.
6
Role of Plasma methylated SEPT9 for Predicting Microvascular Invasion and Tumor Proliferation in Hepatocellular Carcinoma.血浆 SEPT9 甲基化在预测肝细胞癌微血管侵犯和肿瘤增殖中的作用。
Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221144510. doi: 10.1177/15330338221144510.
7
Microvascular invasion risk scores affect the estimation of early recurrence after resection in patients with hepatocellular carcinoma: a retrospective study.微血管侵犯风险评分影响肝癌患者切除术后早期复发的评估:一项回顾性研究。
BMC Med Imaging. 2022 Nov 22;22(1):204. doi: 10.1186/s12880-022-00940-0.
8
Liver Transplant Oncology: Towards Dynamic Tumor-Biology-Oriented Patient Selection.肝移植肿瘤学:迈向以动态肿瘤生物学为导向的患者选择
Cancers (Basel). 2022 May 27;14(11):2662. doi: 10.3390/cancers14112662.
9
Progression of Prothrombin Induced by Vitamin K Absence-II in Hepatocellular Carcinoma.维生素K缺乏诱导蛋白II在肝细胞癌中的进展
Front Oncol. 2021 Nov 10;11:726213. doi: 10.3389/fonc.2021.726213. eCollection 2021.
10
Critical appraisal of TNM versus HKU staging system for postoperative prognostic evaluation of hepatocellular carcinoma.对TNM分期系统与香港大学分期系统用于肝细胞癌术后预后评估的批判性评价。
Ann Transl Med. 2021 Jun;9(11):919. doi: 10.21037/atm-20-7611.
在中国,去γ-羧基凝血酶原与甲胎蛋白对乙型肝炎病毒相关肝细胞癌的诊断评估:一项大规模、多中心研究
PLoS One. 2016 Apr 12;11(4):e0153227. doi: 10.1371/journal.pone.0153227. eCollection 2016.
4
CK19 and Glypican 3 Expression Profiling in the Prognostic Indication for Patients with HCC after Surgical Resection.CK19和磷脂酰肌醇蛋白聚糖3表达谱在肝癌手术切除患者预后指标中的应用
PLoS One. 2016 Mar 15;11(3):e0151501. doi: 10.1371/journal.pone.0151501. eCollection 2016.
5
Heat shock proteins in hepatocellular carcinoma: Molecular mechanism and therapeutic potential.肝细胞癌中的热休克蛋白:分子机制与治疗潜力
Int J Cancer. 2016 Apr 15;138(8):1824-34. doi: 10.1002/ijc.29723. Epub 2015 Aug 19.
6
Cancer statistics in China, 2015.《中国癌症统计数据 2015》
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32. doi: 10.3322/caac.21338. Epub 2016 Jan 25.
7
Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.基于证据的肝细胞癌患者诊断、分期和治疗。
Gastroenterology. 2016 Apr;150(4):835-53. doi: 10.1053/j.gastro.2015.12.041. Epub 2016 Jan 12.
8
Cancer statistics, 2016.癌症统计数据,2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
9
Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin.利用新一代去γ-羧基凝血酶原预测肝细胞癌中的血管侵犯
Br J Cancer. 2016 Jan 12;114(1):53-8. doi: 10.1038/bjc.2015.423. Epub 2015 Dec 17.
10
Predictive factors of pathological vascular invasion in hepatocellular carcinoma within 3 cm and three nodules without radiological vascular invasion.预测 3cm 内且无影像学血管侵犯的三个结节的肝细胞癌中病理性血管侵犯的因素。
Hepatol Res. 2016 Sep;46(10):985-91. doi: 10.1111/hepr.12637. Epub 2016 Feb 4.